Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 30, 2024 (filed on Apr 02, 2024)Insider Name:Bolton StephanieOwnership Type:Direct OwnershipSecurities:Performance Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-1,961Price:--
-
Mar 30, 2024 (filed on Apr 02, 2024)Insider Name:Bolton StephanieOwnership Type:Direct OwnershipSecurities:Performance Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-1,290Price:--
-
Mar 30, 2024 (filed on Apr 02, 2024)Insider Name:Bolton StephanieOwnership Type:Direct OwnershipSecurities:Performance Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-1,706Price:--
-
Mar 30, 2024 (filed on Apr 02, 2024)Insider Name:Bolton StephanieOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-1,330Price:--
-
Mar 30, 2024 (filed on Apr 02, 2024)Insider Name:Bolton StephanieOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-457Price:--
-
Mar 30, 2024 (filed on Apr 02, 2024)Insider Name:Bolton StephanieOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-427Price:--
-
Mar 30, 2024 (filed on Apr 02, 2024)Insider Name:Bolton StephanieOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-573Price:--
-
Mar 30, 2024 (filed on Apr 02, 2024)Insider Name:Bolton StephanieOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-3,643Price:$55.94
-
Mar 30, 2024 (filed on Apr 02, 2024)Insider Name:Bolton StephanieOwnership Type:Direct OwnershipSecurities:Stock Appreciation RightsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:10,746Price:--
-
Mar 30, 2024 (filed on Apr 02, 2024)Insider Name:Bolton StephanieOwnership Type:Direct OwnershipSecurities:Performance Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,915Price:--
Filings by filing date
-
Mar 30, 2024 (filed on Apr 02, 2024)Insider Name:Bolton StephanieOwnership Type:Direct OwnershipSecurities:Performance Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-1,961Price:--
-
Mar 30, 2024 (filed on Apr 02, 2024)Insider Name:Bolton StephanieOwnership Type:Direct OwnershipSecurities:Performance Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-1,290Price:--
-
Mar 30, 2024 (filed on Apr 02, 2024)Insider Name:Bolton StephanieOwnership Type:Direct OwnershipSecurities:Performance Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-1,706Price:--
-
Mar 30, 2024 (filed on Apr 02, 2024)Insider Name:Bolton StephanieOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-1,330Price:--
-
Mar 30, 2024 (filed on Apr 02, 2024)Insider Name:Bolton StephanieOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-457Price:--
-
Mar 30, 2024 (filed on Apr 02, 2024)Insider Name:Bolton StephanieOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-427Price:--
-
Mar 30, 2024 (filed on Apr 02, 2024)Insider Name:Bolton StephanieOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-573Price:--
-
Mar 30, 2024 (filed on Apr 02, 2024)Insider Name:Bolton StephanieOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-3,643Price:$55.94
-
Mar 30, 2024 (filed on Apr 02, 2024)Insider Name:Bolton StephanieOwnership Type:Direct OwnershipSecurities:Stock Appreciation RightsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:10,746Price:--
-
Mar 30, 2024 (filed on Apr 02, 2024)Insider Name:Bolton StephanieOwnership Type:Direct OwnershipSecurities:Performance Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,915Price:--
News
Biz Brief
Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 20 Eastbourne Terrace LONDON W2 6LG |
Tel: | 1-281-8952382 |
Website: | https://www.livanova.com |
IR: | See website |
Key People | ||
William A. Kozy Chairman of the Board | Vladimir A. Makatsaria Chief Executive Officer, Director | Alex Shvartsburg Chief Financial Officer |
Trui Hebbelinck Chief Human Resource Officer | Michael Damon Hutchinson Senior Vice President, Chief Legal Officer and Corporate Secretary |
Business Overview |
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the design, development, manufacture, marketing and selling of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula and other related accessories. It includes the Essenz Perfusion System, the Company's next-generation HLM with an embedded patient monitor for tailored patient care strategies. Neuromodulation segment is engaged in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). The ACS segment is engaged in the development, production, and sale of temporary life support products. |
Financial Overview |
For the fiscal year ended 31 December 2023, LivaNova PLC revenues increased 13% to $1.15B. Net income totaled $17.5M vs. loss of $86.2M. Revenues reflect Cardiopulmonary segment increase of 18% to $589M, Neuromodulation segment increase of 9% to $519.7M, United States segment increase of 11% to $635M, Europe segment increase of 20% to $214.8M. Net Income reflects Impairment of goodwill decrease from $129.4M (expense) to $0K. |
Employees: | 2,900 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $3,316M as of Dec 31, 2023 |
Annual revenue (TTM): | $1,154M as of Dec 31, 2023 |
EBITDA (TTM): | $107.16M as of Dec 31, 2023 |
Net annual income (TTM): | $17.55M as of Dec 31, 2023 |
Free cash flow (TTM): | $39.93M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $320.15M as of Dec 31, 2023 |
Shares outstanding: | 53,956,158 as of Feb 23, 2024 |
Index Membership: | S&P 400 Mid Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |